
Henry Schein, Inc. (NASDAQ:HSIC - Free Report) - Equities researchers at William Blair raised their Q4 2025 earnings per share estimates for Henry Schein in a note issued to investors on Tuesday, August 5th. William Blair analyst B. Vazquez now anticipates that the company will earn $1.31 per share for the quarter, up from their previous forecast of $1.22. The consensus estimate for Henry Schein's current full-year earnings is $4.74 per share. William Blair also issued estimates for Henry Schein's Q1 2026 earnings at $1.25 EPS, Q2 2026 earnings at $1.23 EPS, Q3 2026 earnings at $1.42 EPS, Q4 2026 earnings at $1.35 EPS and FY2026 earnings at $5.24 EPS.
Henry Schein (NASDAQ:HSIC - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.19 by ($0.09). The firm had revenue of $3.24 billion during the quarter, compared to analysts' expectations of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. Henry Schein's revenue for the quarter was up 3.3% on a year-over-year basis. During the same quarter last year, the company posted $1.23 earnings per share.
Several other analysts have also recently commented on HSIC. JPMorgan Chase & Co. lowered their target price on shares of Henry Schein from $80.00 to $76.00 and set an "overweight" rating for the company in a research note on Thursday. Wells Fargo & Company decreased their price objective on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Leerink Partners set a $75.00 price objective on Henry Schein in a research report on Monday, July 14th. UBS Group reduced their target price on Henry Schein from $75.00 to $70.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Evercore ISI decreased their price target on Henry Schein from $78.00 to $70.00 and set an "in-line" rating on the stock in a research note on Wednesday. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Henry Schein currently has a consensus rating of "Hold" and a consensus price target of $75.58.
Check Out Our Latest Research Report on HSIC
Henry Schein Trading Up 0.1%
Shares of NASDAQ:HSIC traded up $0.04 during trading on Friday, reaching $65.94. The stock had a trading volume of 1,931,964 shares, compared to its average volume of 2,156,766. The company has a quick ratio of 0.75, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. The stock has a market cap of $8.00 billion, a P/E ratio of 21.27, a PEG ratio of 2.17 and a beta of 0.81. The business has a fifty day moving average price of $71.07 and a 200-day moving average price of $71.09. Henry Schein has a fifty-two week low of $60.56 and a fifty-two week high of $82.49.
Institutional Trading of Henry Schein
A number of institutional investors have recently modified their holdings of HSIC. Investment Management Corp VA ADV acquired a new stake in shares of Henry Schein in the fourth quarter worth $32,000. Rakuten Securities Inc. purchased a new stake in Henry Schein during the 1st quarter worth $34,000. ANTIPODES PARTNERS Ltd purchased a new position in Henry Schein in the second quarter valued at about $43,000. Steph & Co. purchased a new position in Henry Schein in the second quarter valued at about $44,000. Finally, CX Institutional lifted its stake in shares of Henry Schein by 107.3% during the second quarter. CX Institutional now owns 651 shares of the company's stock worth $48,000 after purchasing an additional 337 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.
Henry Schein Company Profile
(
Get Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Articles

Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.